Arthneeti
NGL Fine Chem LtdQ4 FY24

NGL Fine Chem Ltd Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹2,657P/E: 32.6Market Cap: ₹1.6K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 2

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3
  • The company is experiencing strong demand with volume growth driving topline increases, evidenced by 18%-20% revenue growth in FY24 despite price pressures.
  • Volume growth is expected to continue, supported by increased outsourcing and debottlenecking in existing plants.
  • Long-term objective is to maintain a 15%-17% CAGR in topline growth over the next five years, consistent with historical trends.
  • Focus on expanding in regulated markets (European and US) through new plant commissioning and product registrations, although benefits may take a few years.
  • Growth in Europe expected to emerge in a couple of years once product registrations complete.
  • The company aims to increase market share even at depressed margins, betting on a future recovery in prices and margins.
  • New greenfield projects are considered longer-term with brownfield expansions seen as quicker capacity additions.

See what NGL Fine Chem Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • There is no explicit mention of any current or planned fundraising through debt or equity in the call transcript.
  • The company is focused on modular CAPEX spending for new plant development rather than large lump sum investments.
  • Rahul Nachane mentioned spending Rs. 45 crores initially and planning to spend another Rs. 25 crores subsequently, suggesting planned internal fund deployment.
  • There was no discussion of raising funds externally via equity or debt during the Q&A or closing remarks.
  • The company is cautious about sharing product-specific or financial details to maintain competitive advantage.
  • Overall, no indication of any immediate or near-term fundraising through debt or equity is stated.

See what NGL Fine Chem Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes
  • NGL Fine-Chem is undertaking a new Greenfield plant investment aimed largely at regulated markets (Europe and US), with a total CAPEX of approximately Rs. 140-150 crores.
  • The first phase of the new plant is targeted to start by September (early Q3 FY25) for validation batches, with full commercial production expected by end of calendar year 2025.
  • The company favors modular CAPEX spending: it has spent Rs. 45 crores so far and plans an additional Rs. 25 crores.
  • Brownfield expansions or debottlenecking at existing plants will be considered based on demand and opportunity, offering shorter lead times (6-9 months) versus Greenfield projects (~2 years).
  • No concrete plans yet for new RoW (Rest of World) market plants, but the company remains open to acquisition or expansion opportunities if demand warrants.
  • Outsourcing is increasing to address supply gaps and support volume growth, with related costs rising correspondingly.

Track NGL Fine Chem Ltd — get its next earnings analysis in your feed

Margin guidance

Category 2
- The company targets maintaining a topline growth of around 15% CAGR over the next 5 years, driven primarily by volume growth and some price improvement due to entry into regulated markets (Page 12). - EBITDA margins are expected to gradually improve from current levels (~14.5%-15%) to a range of 17% to 22% in the long run (Pages 9, 12). - The shift toward regulated markets (Europe, US) with 8 products filed in Europe aims to provide higher margin business and reduced pricing pressure (Pages 9, 13). - Asset turn for the new Rs. 140-150 crore greenfield plant is expected to be around 2x, with full utilization likely taking 2-3 years (Page 10-12). - EBITDA margins in FY25 are anticipated within 14%-17% due to higher competitive pressure and conscious strategy to gain market share (Page 9). - Profit after tax nearly doubled in FY24 to Rs. 41.32 crores with continued volume growth driving earnings (Page 4). Overall, earnings and profits are expected to grow steadily with improving margins over the medium term.

Order book

The transcript does not provide specific details on the current or expected order book or pending orders for NGL Fine-Chem Limited. Key points related to orders and capacity include: - No explicit mention of order book size or value was made during the Q&A. - The company is operating at 90-95% capacity utilization, indicating strong demand. - Volume growth has been significant, supported by increased outsourcing to meet market demand. - The management emphasized a cautious growth approach and maintaining market share. - Discussions regarding new product filings and regulatory approvals reflect future growth potential but no direct order backlog figures. - The company prefers confidentiality on product-specific business and does not disclose detailed sales or order book data publicly. Hence, no precise order book or pending order value is disclosed in the provided text.

How does NGL Fine Chem Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisNGL Fine Chem Ltd
Rev 3Mar 2
See where NGL Fine Chem Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does NGL Fine Chem Ltd rank in Pharmaceuticals & Biotechnology?

Compare NGL Fine Chem Ltd against every Pharmaceuticals & Biotechnology company (Q4 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Continue your research

What NGL Fine Chem Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • IOL Chemicals (Q1 FY27)

    Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…

  • Innova Captab (Q1 FY27)

    The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…

  • Glenmark Pharma. (Q1 FY27)

    Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…

  • Strides Pharma (Q1 FY27)

    markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…

Compare:vs Sun Pharmaceutical Industries Ltdvs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →